Pacira BioSciences (PCRX) EV to EBITDA (2011 - 2026)

Pacira BioSciences has reported EV to EBITDA for 16 years, with the latest figure at 177.94 in Q2 2026.

• On a quarterly basis, EV to EBITDA rose 141.12% year-over-year to 177.94 in Q2 2026; TTM through Jun 2026 was 38.21, a 735.62% increase from a year earlier, with the FY2025 full-year figure at 43.02, up 916.62% from the prior year.
• EV to EBITDA was 177.94 for Q2 2026 at Pacira BioSciences, up from 99.42 in the prior quarter.
• The five-year high for EV to EBITDA was 352.85 in Q4 2025, with the low at 550.65 in Q1 2023.
• Average EV to EBITDA over 5 years is 60.36, with a median of 74.58 recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: EV to EBITDA slumped 420.62% in 2023, then jumped 7943.4% in 2025.
• Over 5 years, EV to EBITDA stood at 150.07 in 2022, then surged by 125.91% to 38.88 in 2023, then slumped by 59.76% to 15.65 in 2024, then jumped by 2155.0% to 352.85 in 2025, then tumbled by 49.57% to 177.94 in 2026.
• The last three EV to EBITDA figures came in at 177.94 (Q2 2026), 99.42 (Q1 2026), and 352.85 (Q4 2025), per Business Quant data.